Xenetic Biosciences (XBIO) Q3 2025 earnings summary

Executive summary

• Advanced DNase technology for immuno-oncology, targeting difficult-to-treat cancers, with ongoing preclinical and clinical development, including mechanism-of-action and translational studies for Phase 1 trial preparation.

• Entered a Clinical Trial Services Agreement with PeriNess for exploratory studies in Israeli medical centers.

• Initiated a formal strategic review process, considering options such as sale, asset divestiture, or business combination, including a reverse merger.

• No regulatory approvals for drug candidates to date; revenue is derived from legacy PolyXen technology royalties.

Financial highlights

• Revenue for Q3 2025 was $1.03M, up 67.2% year-over-year, mainly from increased royalties from Takeda.

• Net loss for Q3 2025 was $0.51M; net loss for the nine months ended September 30, 2025 was $2.10M, down from $2.91M in the prior year period.

• Operating costs for Q3 2025 increased 41.1% year-over-year, mainly due to higher R&D and legal expenses; R&D expenses rose 105.6% to $0.8M, and G&A expenses increased 9.3% to $0.8M.

• Cash balance at September 30, 2025 was $4.1M, down from $6.2M at December 31, 2024.

• Working capital at September 30, 2025 was $4.0M.

Outlook and guidance

• Management expects continued operating losses in the near term but believes existing resources, plus $3.9M raised post-quarter, will fund operations for at least 12 months.

• Focus remains on advancing DNase-based oncology technology toward IND submission and Phase 1 initiation.

• Additional long-term capital will be needed to pursue business initiatives; access to future capital is subject to market and company-specific factors.